Please Wait.....
Report
Low-grade glioma- Epidemiology Forecast-2032
Market Report I 2022-08-01 I 80 Pages I DelveInsight
DelveInsight's 'Low-grade glioma- Epidemiology Forecast-2032' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Geography Covered
- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Low-grade glioma Disease Understanding
Low-grade glioma Overview
Low-grade glioma (LGGs) are a diverse group of primary brain tumors that often arise in young, otherwise healthy patients and generally have an indolent course with longer-term survival in comparison with high-grade glioma. Moreover, in this type of brain tumor with a relatively good prognosis and prolonged survival, the potential benefits of treatment must be carefully weighed against potential treatment-related risks.Low-grade astrocytic tumors include diffuse astrocytoma, pilomyxoid astrocytoma, and pleomorphic xanthoastrocytoma (WHO grade II), as well as subependymal giant cell astrocytoma (SEGA) and pilocytic astrocytoma (WHO grade I tumors).
IDH1 and IDH2 are the most commonly mutated genes in low grade glioma, with mutations estimated to occur in > 70% of cases. BRAF V600E point mutations are occasionally observed in pilocytic astrocytoma; the mutations are also observed in nonpilocytic pediatric low-grade glioma, including ganglioglioma, desmoplastic infantile ganglioglioma, and approximately two-thirds of pleomorphic xanthoastrocytomas.
The symptoms include seizure loss of time, feeling of deja vu or jamais vu, trouble speaking and understanding other people speaking, episodes of confusion, numbness or weakness and vision problems.
Low-grade glioma Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of primary brain cancer, total incident population of low-grade glioma, Grade-specific , age specific ,type-specific cases of low-grade glioma the further segmentation done by low-grade glioma cases based on molecular alterations and enhancing and non-enhancing low-grade glioma in the 7MM market covering the United States, EU-5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2019 to 2032.
Key Findings
This section provides glimpse of the LGG epidemiology in the 7MM
Country Wise- Low-grade glioma Epidemiology
- The epidemiology segment also provides the LGG epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
- The total incident population of LGG in the 7MM comprised of 9,078 cases in 2021 and are projected to increase during the forecast period.
- The total incident population of glioma in the United States is 3,654 in 2021.
- The United States contributed to the largest incident population of LGG, accounting for ~ 40% of the 7MM in 2021.
- In the EU-5 countries, the diagnosed prevalence of LGG was found to be maximum in Germany followed by France. While, the least number of cases were found in Spain, in 2021.
- In Japan, the total incident population of LGG is 814 in 2021 and is anticipated to rise during the forecast period.
- In 2021, 2,958 patients accounted for IDH mutation, and 251 accounted for BRAF V600E cases in the United States.
- In 2021, the Grade II non-enhancing LGGs accounted for 1,819 cases in the United States.
- In the United States, there were number of Grade 2 glioma cases are higher than the Grade I cases in 2021.
- In the US, based on age, the maximum cases are in the age group of <18 years i.e. 1,253 followed by 18-44 years, 45-59 years, 60-74 years, and least in ?75 years in 2021.
- Based on the molecular alterations the incident population of LGG is segmented into diffuse astrocytoma, oligodendroglioma, oligoastrocytic tumors, pilocytic astrocytoma, ependymal tumors, and unique astrocytoma variants. In 2021, the diffuse astrocytoma and oligodendroglioma in the United States accounted for 1,161 and 689, respectively
Scope of the Report
- The report covers the descriptive overview of LGG, explaining its causes, signs and symptoms, pathogenesis and diagnosis.
- Comprehensive insight has been provided into the LGG epidemiology and treatment.
- The report provides insight about the historical and forecasted patient pool of Huntington's disease in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- As per DelveInsight's analysis, LGG can be divided into two grades, namely,Grade I and Grade II gliomas.
- The report also encompasses other major segments, i.e., age-specific, type-specific cases of low-grade glioma, incident pool based on molecular alterations, and enhancing/non-enhancing.
Report Highlights
- Eleven Years Forecast
- 7MM Coverage
- Total Incidance cases of LGG
- Age-specific cases of LGG
LGG Report Insights
- Patient Population
- Eleven Years Forecast
- 7MM Coverage
- LGG Epidemiology Segmentation
Key Questions
- What is the disease risk, burden and unmet needs of LGG?
- What is the historical LGG patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of LGG at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to LGG?
- Out of the above-mentioned countries, which country would have the highest incident population of LGG during the study period (2019-2032)?
- At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the LGG.
- Quantify patient populations in the global LGG market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the best opportunities for LGG in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
- The LGG Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology Methodology
5. Disease Background and Overview
5.1. Introduction
5.2. Types
5.2.1. Astrocytoma Tumors
5.2.2. Oligodendroglioma tumors
5.2.3. Molecular Features of Low-grade Glioma
5.3. Symptoms
5.4. Causes and Risk factors
5.5. Diagnosis
5.6. Symptom Management
6. Epidemiology and Patient Population of LGG in the 7MM
6.1. Key Findings
6.2. Assumptions and Rationale
6.3. Total Incident Population of Low-grade Glioma in the 7MM
6.4. The United States
6.4.1. Total Incident Population of Glioma in the United States
6.4.2. Total Incident Population of Low-grade Glioma in the United States
6.4.3. Grade-specific Cases of Low-grade Glioma in the United States
6.4.4. Age-specific Cases of Low-grade Glioma in the United States
6.4.5. Type-specific Cases of Low-grade Glioma in the United States
6.4.6. Low-grade Glioma Cases Based on Molecular Alterations in the United States
6.4.7. Enhancing and Non-enhancing Grade II Glioma cases in the United States
6.5. EU-5 (Germany, Frnace, Italy, Spain, and the United Kingdom)
6.5.1. Total Incident Population of Glioma in the EU-5
6.5.2. Total Incident Population of Low-grade Glioma in the EU-5
6.5.3. Grade-specific Cases of Low-grade Glioma in the EU-5
6.5.4. Age-specific Cases of Low-grade Glioma in the EU-5
6.5.5. Type-specific cases of Low-grade Glioma in the EU-5
6.5.6. Low-grade Glioma Cases Based on Molecular Alterations in the EU-5
6.5.7. Enhancing and Non-enhancing Grade II Glioma cases in the EU-5
6.6. Japan
6.6.1. Total Incident Population of Glioma in Japan
6.6.2. Total Incident Population of Low-grade Glioma in Japan
6.6.3. Grade-specific Cases of Low-grade Glioma in Japan
6.6.4. Age-specific Cases of Low-grade Glioma in Japan
6.6.5. Type-specific cases of Low-grade Glioma in Japan
6.6.6. Low-grade Glioma Cases Based on Molecular Alterations in Japan
6.6.7. Enhancing and Non-enhancing Grade II Glioma cases in Japan
7. Unmeet need
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About Delveinsight
Table 1 Summary of Low Grade Glioma Market, and Epidemiology (2019-2032)
Table 2 Adult Glioma
Table 3 Adult Glioma
Table 4 Adult Glioma
Table 5 Indication and Timing for RT
Table 6 Optimal Dose of RT and Target Volume Based on Risk Stratification
Table 7 Key treatment Recommendations for Adult Patients With Common Grade 2 Diffuse Glioma
Table 8 Total Incident Population of Low-grade Glioma in the 7MM (2019-2032)
Table 9 Total Incident Population of Primary Brain Cancer in the US (2019-2032)
Table 10 Total Incident Population of Low-grade Glioma in the US (2019-2032)
Table 11 Grade-specific Cases of Low-grade Glioma in the US (2019-2032)
Table 12 Age-specific Cases of Low-grade Glioma in the US (2019-2032)
Table 13 Type-specific Cases of Low-grade Glioma in the US (2019-2032)
Table 14 Low-grade Glioma Cases Based on Molecular Alterations in the US (2019-2032)
Table 15 Enhancing and Non-enhancing Low-grade Glioma Cases in the US (2019-2032)
Table 16 Total Incident Population of Primary Brain Cancer in EU5 (2019-2032)
Table 17 Total Incident Population of Low-grade Glioma in EU5 (2019-2032)
Table 18 Grade-specific Cases of Low-grade Glioma in EU5 (2019-2032)
Table 19 Age-specific Cases of Low-grade Glioma in EU5 (2019-2032)
Table 20 Age-specific Cases of Low-grade Glioma in EU5 (2019-2032)
Table 21 Low-grade Glioma Cases Based on Molecular Alterations in EU5 (2019-2032)
Table 22 Enhancing and Non-enhancing Low-grade Glioma cases in EU5 (2019-2032)
Table 23 Total Incident Population of Primary Brain Cancer Japan (2019-2032)
Table 24 Total Incident Population of Low-grade Glioma in Japan (2019-2032)
Table 25 Grade-specific Cases of Low-grade Glioma in Japan (2019-2032)
Table 26 Age-specific Cases of Low-grade Glioma in Japan (2019-2032)
Table 27 Type-specific Cases of Low-grade Glioma in Japan (2019-2032)
Table 28 Low-grade Glioma Cases Based on Molecular Alterations in Japan (2019-2032)
Table 29 Enhancing and Non-enhancing Low-grade Glioma cases in Japan (2019-2032)
Figure 1: WHO classification of Brain Cancer
Figure 2: Global Heat Map of Brain and CNS Tumor
Figure 3: Total Incident Population of Low-grade Glioma in the 7MM (2019-2032)
Figure 4: Total Incident Population of Glioma in the US (2019-2032)
Figure 5: Total Incident Population of Low-grade Glioma in the US (2019-2032)
Figure 6: Grade-specific Cases of Low-grade Glioma in the US (2019-2032)
Figure 7: Age-specific Cases of Low-grade Glioma in the US (2019-2032)
Figure 8: Type-specific Cases of Low-grade Glioma in the US (2019-2032)
Figure 9: Low-grade Glioma Cases Based on Molecular Alterations in the US (2019-2032)
Figure 10: Enhancing and Non-enhancing Grade II Glioma cases in the US (2019-2032)
Figure 11: Total Incident Population of Glioma in the EU-5 (2019-2032)
Figure 12: Total Incident Population of Low-grade Glioma in the EU-5 (2019-2032)
Figure 13: Grade-specific Cases of Low-grade Glioma in the EU-5 (2019-2032)
Figure 14: Age-specific Cases of Low-grade Glioma in the EU-5 (2019-2032)
Figure 15: Type-specific Cases of Low-grade Glioma in the EU-5 (2019-2032)
Figure 16: Low-grade Glioma Cases Based on Molecular Alterations in the EU-5 (2019-2032)
Figure 17: Enhancing and Non-enhancing Grade II Glioma cases in the EU-5 (2019-2032)
Figure 18: Total Incident Population of Glioma in Japan (2019-2032)
Figure 19: Total Incident Population of Low-grade Glioma in Japan (2019-2032)
Figure 20: Grade-specific Cases of Low-grade Glioma in Japan (2019-2032)
Figure 21: Age-specific Cases of Low-grade Glioma in Japan (2019-2032)
Figure 22: Type-specific Cases of Low-grade Glioma in Japan (2019-2032)
Figure 23: Low-grade Glioma Cases Based on Molecular Alterations in Japan (2019-2032)
Figure 24: Enhancing and Non-enhancing Grade II Glioma cases in Japan (2019-2032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security